Leptin induced genes

A method for determining whether a compound can be used to modulate body weight, comprising:

• a) measuring activity of one or proteins selected from the group consisting of LIG46, LIG56, Tgtp, LRG-47, RC10-II, and Stra13 in a sample in the presence and absence of the compound;
• and
• b) identifying the compound as useful for modulating body weight when the activity of the selected one or more proteins in the presence of the compound differs from the activity of the selected one or more protein in the absence of the compound.

A method for determining whether a compound can be used to modulate body weight, comprising:

• a) measuring expression level of one or more genes selected from the group consisting of LIG46, LIG56, Tgtp, LRG-47, RC10-II, and Stra13 in sample of cells isolated from a mammal treated with the compound and in a sample of cells isolated from an untreated mammal;
• and
• b) identifying the compound as useful for modulating body weight when the expression level of the selected one or more genes in the sample of cells isolated from the treated mammal differs from the expression of the selected one or more genes in the sample of cells isolated from the untreated mammal.

A method for determining whether a compound can be used to modulate body weight, comprising:

• a) measuring activity level of one or more proteins selected from the group consisting of LIG46, LIG56, Tgtp, LRG-47, RC10-II, and Stra13 in sample of cells isolated from a mammal treated with the compound and in a sample of cells isolated from an untreated mammal;
• and
• b) identifying the compound as useful for modulating body weight when the activity level of the selected one or more proteins in the sample of cells isolated from the treated mammal differs from the activity level of the one or more selected proteins in the sample of cells isolated from the untreated mammal.

An isolated polypeptide selected from the group consisting of:

• a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6;
• b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7 under stringent conditions;
• c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

A method for treating a weight disorder comprising administering a molecule which reduces expression of activity of protein selected from the group consisting of LIG46, LIG56, Tgtp, LRP-47, RC10-II, and Stra13.